StreetInsider.com News Articles

Disc Medicine (IRON) Reiterated at Buy by Stifel

Wed, 03 Jun 2026 06:56:48 -0400

Stifel analyst Stephen Willey reiterated a Buy rating and $111.00 price target on Disc Medicine (NASDAQ: IRON).

The analyst commented, "P2 RALLY-MF data (DISC-0974 in MFrelated anemia) were featured as an oral presentation at today’s ASCO meeting. Results are largely-unsurprising/consistent and remain impressive – with DISC-0974 continuing to demonstrate compelling efficacy agnostic to baseline anemia severity and concomitant JAKi therapy. Additional RALLY-MF data is anticipated in 4Q26 and management expects to have an end-of-P2 meeting with FDA by YE26. Given the P2 RALLY-MF trial is targeting ~30 patients/cohort and today’s update now includes >30 efficacy-evaluable non-TD patients, we expect the YE26

Disc Medicine reports positive anemia trial results at ASCO meeting

Tue, 02 Jun 2026 08:00:18 -0400

Disc Medicine Inc. (NASDAQ: IRON) presented updated data from its RALLY-MF Phase 2 trial of DISC-0974 for myelofibrosis-associated anemia at the American Society of Clinical Oncology Annual Meeting in Chicago.

The trial enrolled 61 adult patients with myelofibrosis and anemia, with 50 patients having sufficient follow-up for analysis. Patients were divided into three groups: non-transfusion dependent (31 patients), transfusion dependent with low burden (11 patients), and transfusion dependent with high burden (8 patients).

Results showed 55% of non-transfusion dependent patients achieved a hemoglobin increase of at least 1.5 g/dL for 12 weeks or longer. Among transfusion dependent patients with low burden, 64%

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

WATERTOWN, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today presents updated data from the RALLY-MF Phase 2 trial of DISC-0974 in anemia of MF at the ASCO Annual Meeting in Chicago, IL. In this updated data set, treatment with DISC-0974 shows substantial reductions in

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

Disc Medicine Presents Updated Positive Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

Tue, 02 Jun 2026 08:00:00 -0400

Demonstrated meaningful, durable overall anemia responses across all patient subgroups, regardless of baseline transfusion status
Anemia response was seen independent of concomitant JAK inhibitor therapy use

Disc Medicine launches expanded access program for bitopertin

Mon, 01 Jun 2026 08:30:38 -0400

Disc Medicine Inc. (NASDAQ: IRON) announced the launch of an expanded access program for bitopertin, an investigational treatment for patients with erythropoietic protoporphyria and X-linked protoporphyria in the United States.

The program provides access to bitopertin for eligible patients ages 12 and above who lack satisfactory therapeutic alternatives and meet additional eligibility criteria. The expanded access program is available while bitopertin undergoes evaluation in the Phase 3 APOLLO clinical trial.

Bitopertin is an oral glycine transporter 1 inhibitor designed to modulate heme biosynthesis. The company expects topline data from the APOLLO study in the fourth quarter of 2026, followed by submission of

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

WATERTOWN, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today announced the launch of an expanded access program (EAP) for bitopertin for eligible

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

Disc Medicine Launches Expanded Access Program for Bitopertin for EPP Patients

Mon, 01 Jun 2026 08:30:00 -0400

The expanded access program (EAP) is available to eligible patients with erythropoietic protoporphyria (EPP) and provides access to bitopertin prior to regulatory decision
Bitopertin, an oral glycine transporter 1 (GlyT1) inhibitor, is being evaluated in the Phase 3 APOLLO clinical trial, with topline data anticipated in Q4 2026

Disc Medicine (IRON) PT Raised to $80 at Morgan Stanley

Thu, 14 May 2026 08:52:36 -0400

Morgan Stanley analyst Sean Laaman raised the price target on Disc Medicine (NASDAQ: IRON) to $80.00 (from $75.00) while maintaining a Overweight rating.

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Tue, 12 May 2026 09:30:00 -0400

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia
Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405 trial in progress for polycythemia vera
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Tue, 12 May 2026 09:30:00 -0400

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia
Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405 trial in progress for polycythemia vera
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Tue, 12 May 2026 09:30:00 -0400

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia
Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405 trial in progress for polycythemia vera
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2026 Congress

Tue, 12 May 2026 09:30:00 -0400

Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia
Additional abstracts highlighting updates on HELIOS open label extension study of bitopertin in EPP, EPP LIGHT study (patient survey on life and health impact of disease), and DISC-3405 trial in progress for polycythemia vera
Management will host a corporate update conference call on Monday, June 15 at 8:00 am ET

Disc Medicine to Participate in Upcoming Investor Conferences

Mon, 11 May 2026 08:30:00 -0400

WATERTOWN, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in fireside chats at two upcoming investor conferences:

H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.
Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at

Disc Medicine to Participate in Upcoming Investor Conferences

Mon, 11 May 2026 08:30:00 -0400

H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.
Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at

Disc Medicine to Participate in Upcoming Investor Conferences

Mon, 11 May 2026 08:30:00 -0400

H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.
Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at

Disc Medicine to Participate in Upcoming Investor Conferences

Mon, 11 May 2026 08:30:00 -0400

H.C. Wainwright 3rd Annual BioConnect Investor Conference on Tuesday, May 19th at 4:30 p.m. ET.
Jefferies Global Healthcare Conference on Wednesday, June 3rd at 3:10 p.m. ET.

Live webcasts of the fireside chats will be available through the investor relations section of the Company's website at

Disc Medicine (IRON) Misses Q1 EPS by 1c

Tue, 05 May 2026 10:15:13 -0400

Disc Medicine (NASDAQ: IRON) reported Q1 EPS of ($1.65), $0.01 worse than the analyst estimate of ($1.64).

For earnings history and earnings-related data on Disc Medicine (IRON) click here.

Form 10-Q Disc Medicine, Inc. For: Mar 31

Tue, 05 May 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260505/26430623.html

Form 10-Q Disc Medicine, Inc. For: Mar 31

Tue, 05 May 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20260505/26430623.html

Form 8-K Disc Medicine, Inc. For: May 05

Tue, 05 May 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260505/26430613.html

Form 8-K Disc Medicine, Inc. For: May 05

Tue, 05 May 2026 08:32:00 -0400

si-local-file:///var/storage/secattach/20260505/26430613.html